Ionis Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) develops and commercializes RNA-targeted therapeutics for patients with rare diseases and other unmet medical needs. The company utilizes its proprietary antisense technology platform to design drugs that modulate RNA and protein expression; its marketed products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Waylivra (volanesorsen) for rare cardiovascular and metabolic diseases; and its pipeline encompasses candidates such as pelacarsen for cardiovascular disease, olezarsen for familial chylomicronemia syndrome and familial partial lipodystrophy, and donidalorsen for hereditary angioedema. Ionis operates primarily in the biotechnology sector, targeting pharmaceutical companies through licensing agreements and direct commercialization in select markets, with global operations spanning the United States, Europe, and other regions. Founded in 1989 and headquartered in Carlsbad, California, the company maintains subsidiaries including Akcea Therapeutics, which focuses on commercializing certain antisense medicines prior to its integration into Ionis. In recent developments, Ionis completed the acquisition of certain assets from Novartis in 2024, including rights to pelacarsen; announced positive Phase 3 topline results for olezarsen in severe hypertriglyceridemia in mid-2025; and entered a strategic collaboration with Moderna in late 2024 to develop antisense-based therapies for cardiovascular indications. Additionally, the company reported its Q3 2025 financial results in November 2025, highlighting pipeline advancements and royalty revenues exceeding $200 million from Spinraza, alongside preparations for multiple regulatory filings in 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Amova Asset Management Americas Inc. Has $6.13 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS
Ionis Pharmaceuticals: The Heartbreak Is Priced In
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
Ionis to hold second quarter 2026 financial results webcast
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
Levi & Korsinsky Notifies Investors of a Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals (IONS)
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals